Literature DB >> 11016657

Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies.

G L Scheffer1, M Kool, M Heijn, M de Haas, A C Pijnenborg, J Wijnholds, A van Helvoort, M C de Jong, J H Hooijberg, C A Mol, M van der Linden, J M de Vree, P van der Valk, R P Elferink, P Borst, R J Scheper.   

Abstract

Tumor cells may display a multidrug resistance phenotype by overexpression of ATP binding cassette transporter genes such as multidrug resistance (MDR) 1 P-glycoprotein (P-gp) or the multidrug resistance protein 1 (MRP1). MDR3 P-gp is a close homologue of MDR1 P-gp, but its role in MDR is probably minor and remains to be established. The MRP1 protein belongs to a family of at least six members. Three of these, i.e., MRP1, MRP2, and MRP3, can transport MDR drugs and could be involved in MDR. The substrate specificity of the other family members remains to be defined. Specific monoclonal antibodies are required for wide-scale studies on the putative contribution of these closely related transporter proteins to MDR. In this report, we describe the extensive characterization of a panel of monoclonal antibodies (Mabs) detecting several MDR-related transporter proteins in both human and animal tissues. The panel consists of P3II-1 and P3II-26 for MDR3 P-gp; MRPr1, MRPm6, MRPm5, and MIB6 for MRP1; M2I-4, M2II-12, M2III-5 and M2III-6 for MRP2; M3II-9 and M3II-21 for MRP3; and M5I-1 and M5II-54 for MRP5. All Mabs in the panel appeared to be fully specific for their cognate antigens, both in Western blots and cytospin preparations, as revealed by lack of cross-reactivity with any of the other family members. Indeed, all Mabs were very effective in detecting their respective antigens in cytospins of transfected cell lines, whereas in flow cytometric and immunohistochemical analyses, distinct differences in reactivity and suitability were noted. These Mabs should become valuable tools in studying the physiological functions of these transporter proteins, in screening procedures for the absence of these proteins in hereditary metabolic (liver) diseases, and in studying the possible contributions of these molecules to MDR in cancer patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11016657

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

Review 1.  Efflux transporters as a novel herbivore countermechanism to plant chemical defenses.

Authors:  Jennifer S Sorensen; M Denise Dearing
Journal:  J Chem Ecol       Date:  2006-05-23       Impact factor: 2.626

Review 2.  Application of pharmacological approaches to plant-mammal interactions.

Authors:  Jennifer S Sorensen; Michele M Skopec; M Denise Dearing
Journal:  J Chem Ecol       Date:  2006-05-23       Impact factor: 2.626

3.  Mrp1 localization and function in cardiac mitochondria after doxorubicin.

Authors:  Paiboon Jungsuwadee; Ramaneeya Nithipongvanitch; Yumin Chen; Terry D Oberley; D Allan Butterfield; Daret K St Clair; Mary Vore
Journal:  Mol Pharmacol       Date:  2009-02-20       Impact factor: 4.436

4.  Diminished expression of multidrug resistance-associated protein 1 (MRP1) in bronchial epithelium of COPD patients.

Authors:  Margaretha van der Deen; Hendrik Marks; Brigitte W M Willemse; Dirkje S Postma; Michael Müller; Egbert F Smit; George L Scheffer; Rik J Scheper; Elisabeth G E de Vries; Wim Timens
Journal:  Virchows Arch       Date:  2006-10-27       Impact factor: 4.064

5.  Multidrug resistance-associated protein 9 (ABCC12) is present in mouse and boar sperm.

Authors:  Nobuhito Ono; Ingrid Van der Heijden; George L Scheffer; Koen Van de Wetering; Elizabeth Van Deemter; Marcel De Haas; Arjan Boerke; Bart M Gadella; Dirk G De Rooij; Jacques J Neefjes; Tom A M Groothuis; Lauran Oomen; Lenny Brocks; Toshihisa Ishikawa; Piet Borst
Journal:  Biochem J       Date:  2007-08-15       Impact factor: 3.857

6.  Effects of Lewis Y antigen on the gene expression of multiple drug resistance-associated proteins in human ovarian cancer RMG-I-H cells.

Authors:  Song Gao; Qing Liu; Xinyan Wang; Bei Lin; Shulan Zhang
Journal:  Med Oncol       Date:  2009-09-23       Impact factor: 3.064

7.  MRP3: a molecular target for human glioblastoma multiforme immunotherapy.

Authors:  Chien-Tsun Kuan; Kenji Wakiya; James E Herndon; Eric S Lipp; Charles N Pegram; Gregory J Riggins; Ahmed Rasheed; Scott E Szafranski; Roger E McLendon; Carol J Wikstrand; Darell D Bigner
Journal:  BMC Cancer       Date:  2010-09-01       Impact factor: 4.430

8.  Mrp4 confers resistance to topotecan and protects the brain from chemotherapy.

Authors:  Markos Leggas; Masashi Adachi; George L Scheffer; Daxi Sun; Peter Wielinga; Guoqing Du; Kelly E Mercer; Yanli Zhuang; John C Panetta; Brad Johnston; Rik J Scheper; Clinton F Stewart; John D Schuetz
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

9.  Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha.

Authors:  J van der Heijden; M C de Jong; B A C Dijkmans; W F Lems; R Oerlemans; I Kathmann; C G Schalkwijk; G L Scheffer; R J Scheper; G Jansen
Journal:  Ann Rheum Dis       Date:  2004-02       Impact factor: 19.103

10.  Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs.

Authors:  J van der Heijden; M C de Jong; B A C Dijkmans; W F Lems; R Oerlemans; I Kathmann; G L Scheffer; R J Scheper; Y G Assaraf; G Jansen
Journal:  Ann Rheum Dis       Date:  2004-02       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.